French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Tuesday that it has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from privately held Dren Bio Inc, strengthening its immunology portfolio.

Now renamed SAR448501, the asset demonstrated strong B-cell depletion in pre-clinical and early clinical studies targeting autoimmune diseases with high unmet need, including lupus.

The molecule engages specific myeloid cells to induce targeted phagocytosis, aiming to reset the adaptive immune system and enable sustained, treatment-free remission.

Sanofi acquired DR-0201 through the purchase of Dren 0201 Inc, a Dren Bio affiliate, for an upfront payment of USD600m. The deal includes potential milestone payments of up to USD1.3bn tied to development and launch outcomes.

This acquisition aligns with Sanofi's strategy to become a global leader in immunology.

Dren Bio will continue operating independently, advancing its pipeline of antibody therapeutics.